Crown Bioscience Inc.: Crown Bioscience Releases Scientific Posters Detailing Innovations in Preclinical Cancer Pharmacology

Presentation of Posters by Expert Scientists Now Available On-Demand on Crown
Bioscience's Website https://www.crownbio.com/eortc17-posters 

SANTA CLARA, Calif., 2017-12-07 16:39 CET (GLOBE NEWSWIRE) --
Crown Bioscience, a wholly-owned subsidiary of Crown Bioscience International
(TWSE:ticker 6554) and a global drug discovery and development services company
providing translational platforms to advance oncology, inflammation,
cardiovascular and metabolic disease research, releases scientific posters
narrated by leading scientists. These posters were presented at the recent
AACR-NCI-EORTC International Conference on Molecular Targets and Cancer
Therapeutics and are now available on-demand on Crown Bioscience's website,
https://www.crownbio.com/eortc17-posters. 

Crown Bioscience presented more than a dozen scientific posters describing
innovations in the field of preclinical cancer research at AACR-NCI-EORTC 2017.
The most compelling work is now available on-demand and narrated by Crown
Bioscience's scientific experts. The library of poster presentations includes
Dr. Henry Li presenting, "Transcriptomic analysis of patient-derived xenografts
reveals heterogeneity in human and mouse stroma/immune compartments", Dr. Jie
Cai describing "The World's Largest, Well-Characterized PDX Collection", and
Dr. Nektaria Papadopoulou detailing the "Interrogation of Checkpoint Inhibitors
in Bioluminescent Orthotopic Syngeneic Models of Hepatocellular Carcinoma",
among others. 

"I am excited to share Crown Bioscience's cutting-edge research with colleagues
that were not able to attend AACR-NCI-EORTC," said Dr. Henry Li, Crown
Bioscience's Vice President of Biomarker & Diagnostic Technology. "The work
presented will help researchers understand how to identify critical biomarkers
and improve evaluation of cancer therapies and immunotherapies." 

"Crown Bioscience is committed to making valuable contributions to the
scientific community," said Laurie Heilmann, Crown Bioscience's Chief Business
Officer. "By providing these posters, narrated by the experts behind the
science, we hope to deliver insights researchers can use to advance their
preclinical drug development programs." 

The library of narrated posters can be found on Crown Bioscience's website,
https://www.crownbio.com/eortc17-posters. 

About Crown Bioscience Inc.
Crown Bioscience is a global drug discovery and development solutions company
providing translational platforms to advance oncology, inflammation and
metabolic disease research. With an extensive portfolio of relevant models and
predictive tools, Crown Bioscience enables clients to deliver superior clinical
candidates. 

Media Enquiries:
Jody Barbeau
Crown Bioscience Inc.
[e-mail]